AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16732143 — intervention group
Group type: EXPERIMENTAL
Intervention: Three daily doses of dexamethasone
Number of subjects: 90
Study 16732143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 15465501 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai chi training (1‐hour class held twice weekly for 12 weeks)
Number of subjects: 30
Study 15465501 — intervention group
Group type: COMPARATOR
Intervention: Usual care (pharmacologic therapy and dietary and exercise counseling)
Number of subjects: 30
Study 11394516 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 5% (100 mg in 7.5% glucose)
Number of subjects: 60
Study 11394516 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaine 10% (100 mg diluted with 1 ml cerebrospinal fluid)
Number of subjects: 60
Study 11394516 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaine 10%
Number of subjects: 60
Study 9555823 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025% tretinoin cream containing polyolprepolymer‐2
Number of subjects: 271
Study 9555823 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025% tretinoin cream (commercially available)
Number of subjects: 271
Study 9555823 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 271
Study 7672871 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin (15 mg/kg per day) given in one (qd, n = 10) or two equal injections (b.i.d., n = 12) for durations of 7‐11 days
Number of subjects: 22
Study 7672871 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy neonates)
Number of subjects: 22
Study 7672871 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin (qd and b.i.d. administration)
Number of subjects: 22
Study 2646469 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified insulin therapy (IIT) with free mixtures of regular and intermediate (12 hrs)‐acting insulin
Number of subjects: 52
Study 2646469 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified insulin therapy (IIT) with basal and prandial insulin treatment (preprandial injections of regular insulin, and ultralente (24 hrs‐acting) or intermediate insulin for basal demand)
Number of subjects: 52
Study 2646469 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified insulin therapy (IIT)
Number of subjects: 52
Study 31477497 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (EMPA)
Number of subjects: 0
Study 31477497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28390403 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-offset community supported agriculture participation with reduced-price shares, nutrition education classes, and kitchen tools.
Number of subjects: 0
Study 28390403 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention group (control).
Number of subjects: 0
Study 26202150 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel recombinant human FSH (rhFSH, FE 999049) at doses of 5·2‐12·1 μg/day
Number of subjects: 265
Study 26202150 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel recombinant human FSH (rhFSH, FE 999049)
Number of subjects: 265
Study 22944596 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular (BiV) pacing
Number of subjects: 177
Study 22944596 — intervention group
Group type: COMPARATOR
Intervention: Right ventricular apical (RVA) pacing
Number of subjects: 177
Study 22944596 — intervention group
Group type: EXPERIMENTAL
Intervention: DYS at 1 month
Number of subjects: 177
Study 22944596 — intervention group
Group type: EXPERIMENTAL
Intervention: RVA pacing
Number of subjects: 177
Study 21732110 — intervention group
Group type: EXPERIMENTAL
Intervention: Canaloplasty
Number of subjects: 109
Study 21732110 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cataract-canaloplasty surgery
Number of subjects: 109
Study 21732110 — intervention group
Group type: COMPARATOR
Intervention: All study eyes
Number of subjects: 109
Study 20028262 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg intravitreal ranibizumab (IVR) injection
Number of subjects: 30
Study 20028262 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 30
Study 16954164 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic euglycemic clamp
Number of subjects: 9
Study 16954164 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 9
Study 16954164 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid infusion
Number of subjects: 9
Study 15105192 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol 10 mg
Number of subjects: 72
Study 15105192 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 20 mg
Number of subjects: 72
Study 15105192 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 30 mg
Number of subjects: 72
Study 15105192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 11368733 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol xinafoate, 42 microg twice per day (salmeterol‐minus group)
Number of subjects: 175
Study 11368733 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol xinafoate, 42 microg twice per day (salmeterol‐plus group)
Number of subjects: 175
Study 9038597 — intervention group
Group type: EXPERIMENTAL
Intervention: RRR-alpha-tocopherol
Number of subjects: 0
Study 9038597 — intervention group
Group type: EXPERIMENTAL
Intervention: RRR-alpha-tocopheryl acetate
Number of subjects: 0
Study 9038597 — intervention group
Group type: EXPERIMENTAL
Intervention: RRR-alpha-tocopherol (free phenol form)
Number of subjects: 0
Study 9038597 — intervention group
Group type: COMPARATOR
Intervention: RRR-alpha-tocopherol and RRR-alpha-tocopheryl acetate (administered in equal doses)
Number of subjects: 0
Study 8316388 — intervention group
Group type: EXPERIMENTAL
Intervention: Bier's block with 0.6 mg of atropine in 10 ml of saline
Number of subjects: 33
Study 8316388 — intervention group
Group type: COMPARATOR
Intervention: 10 ml of saline
Number of subjects: 33
Study 3555034 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg orally every 12 hours (or 500 mg for the 13-year-old) for 2 to 8 weeks
Number of subjects: 12
Study 3555034 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin and azlocillin administered intravenously for at least two weeks
Number of subjects: 12
Study 29394325 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (1 mA for 20 min on five consecutive days) combined with speech fluency intervention (choral and metronome-timed speech)
Number of subjects: 30
Study 29394325 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation combined with speech fluency intervention (choral and metronome-timed speech)
Number of subjects: 30
Study 29394325 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (1 mA for 20 min on five consecutive days) combined with speech fluency intervention
Number of subjects: 30
Study 27472855 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilization exercise
Number of subjects: 40
Study 27472855 — intervention group
Group type: COMPARATOR
Intervention: Routine exercise
Number of subjects: 40
Study 26554670 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS) in addition to Tinnitus Retraining Therapy (TRT)
Number of subjects: 0
Study 26554670 — intervention group
Group type: COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation (tDCS) in addition to Tinnitus Retraining Therapy (TRT)
Number of subjects: 0
Study 23589371 — intervention group
Group type: EXPERIMENTAL
Intervention: Preladenant 5 mg twice a day
Number of subjects: 140
Study 21551007 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet with endurance training in fasted state (n = 10)
Number of subjects: 27
Study 21551007 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet with endurance training in carbohydrate-fed state (n = 10)
Number of subjects: 27
Study 21551007 — intervention group
Group type: COMPARATOR
Intervention: High-fat diet without training (control group, n = 7)
Number of subjects: 27
Study 18451391 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-incision total hip arthroplasty
Number of subjects: 72
Study 18451391 — intervention group
Group type: COMPARATOR
Intervention: Mini-posterior-incision total hip arthroplasty
Number of subjects: 72
Study 16921788 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estradiol 2 mg/day for 12 weeks
Number of subjects: 41
Study 16921788 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol 50 microg/day (7-day patches) for 12 weeks
Number of subjects: 41
Study 16921788 — intervention group
Group type: COMPARATOR
Intervention: Comparison between oral and transdermal therapy
Number of subjects: 41
Study 12915972 — intervention group
Group type: EXPERIMENTAL
Intervention: HT Immersion Medical Colonoscopy Simulator (module 3 or 4)
Number of subjects: 25
Study 11120762 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiologic T and E replacement
Number of subjects: 59
Study 11120762 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal of both T and E
Number of subjects: 59
Study 11120762 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal of only T
Number of subjects: 59
Study 11120762 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal of only E
Number of subjects: 59
Study 11120762 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing both T and E
Number of subjects: 59
Study 9212967 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrifugal pump
Number of subjects: 14
Study 9212967 — intervention group
Group type: COMPARATOR
Intervention: Roller pump
Number of subjects: 14
Study 9212967 — intervention group
Group type: COMPARATOR
Intervention: Pulsatile pump
Number of subjects: 14
Study 9212967 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 14
Study 8427165 — intervention group
Group type: EXPERIMENTAL
Intervention: Encainide and flecainide
Number of subjects: 0
Study 8427165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3669283 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuzonam (CZON) administered by intravenous injection or intravenous drip infusion, 1 g twice daily for 4 to 7 days (8 g to 14 g in total)
Number of subjects: 13
Study 3669283 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuzonam (CZON)
Number of subjects: 13
Study 29754930 — intervention group
Group type: EXPERIMENTAL
Intervention: short time flow-mediated vasodilation (stFMD)
Number of subjects: 82
Study 28358178 — intervention group
Group type: EXPERIMENTAL
Intervention: Storz® C‐MAC™ videolaryngoscopy
Number of subjects: 80
Study 28358178 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscopy (Macintosh®)
Number of subjects: 80
Study 26410046 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA) with modern medical treatment (MMT)
Number of subjects: 55
Study 26410046 — intervention group
Group type: COMPARATOR
Intervention: Modern medical treatment (MMT) alone
Number of subjects: 55
Study 23410803 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Condition (N = 857)
Number of subjects: 1716
Study 23410803 — intervention group
Group type: COMPARATOR
Intervention: Basic Condition (N = 859)
Number of subjects: 1716
Study 21397567 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab (24 mg per day or 12 mg per day intravenously for 2 or 3 annual cycles)
Number of subjects: 334
Study 21397567 — intervention group
Group type: COMPARATOR
Intervention: Interferon beta-1a (44 μg subcutaneously three times per week)
Number of subjects: 334
Study 21397567 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab (for patients with baseline EDSS ≥2)
Number of subjects: 334
Study 21397567 — intervention group
Group type: COMPARATOR
Intervention: Interferon beta-1a (for patients with baseline EDSS ≥2)
Number of subjects: 334
Study 18347652 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-enriched recovery (0.7 g.kg(‐1).h(‐1) protein)
Number of subjects: 12
Study 18347652 — intervention group
Group type: COMPARATOR
Intervention: Control recovery (0.1 g.kg(‐1).h(‐1) protein)
Number of subjects: 12
Study 17015500 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based mentoring intervention (biweekly until the infant's first birthday)
Number of subjects: 181
Study 17015500 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based mentoring intervention (having > or = 2 intervention visits)
Number of subjects: 181
Study 17015500 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based mentoring intervention (having > or = 6 visits)
Number of subjects: 181
Study 17015500 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based mentoring intervention
Number of subjects: 181
Study 17015500 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 181
Study 12694140 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow rewarming (0.24 +/- 0.09 degrees C)
Number of subjects: 100
Study 12694140 — intervention group
Group type: COMPARATOR
Intervention: Control group (0.48 +/- 0.09 degrees C)
Number of subjects: 100
Study 12694140 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-mental state examination scores
Number of subjects: 100
Study 14728824 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulants therapy
Number of subjects: 86
Study 14728824 — intervention group
Group type: COMPARATOR
Intervention: Control group (no anticoagulants)
Number of subjects: 86
Study 10678121 — intervention group
Group type: EXPERIMENTAL
Intervention: Huperzine-A capsules (Hup) 50 micrograms, 2 capsules b.i.d. for 4 weeks
Number of subjects: 68
Study 10678121 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch and lactose), 2 capsules b.i.d. for 4 weeks
Number of subjects: 68
Study 10678121 — intervention group
Group type: EXPERIMENTAL
Intervention: Huperzine-A capsules (Hup)
Number of subjects: 68
Study 8932546 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizolastine 5 mg
Number of subjects: 8
Study 8932546 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizolastine 10 mg
Number of subjects: 8
Study 8932546 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizolastine 15 mg
Number of subjects: 8
Study 8932546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1875406 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment groups (n = 25)
Number of subjects: 25
Study 1875406 — intervention group
Group type: COMPARATOR
Intervention: Assessment only control group (n = 9)
Number of subjects: 25
Study 6342360 — intervention group
Group type: EXPERIMENTAL
Intervention: Education
Number of subjects: 81
Study 6342360 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support therapy group
Number of subjects: 81
Study 3485932 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin
Number of subjects: 219
Study 3485932 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 219
Study 3485932 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 219
Study 3485932 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin
Number of subjects: 219
Study 31606887 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation program
Number of subjects: 96
Study 31606887 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 96
Study 29413495 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory muscle training (RMT)
Number of subjects: 41
Study 29413495 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 41
Study 28150856 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) in addition to pulmonary rehabilitation
Number of subjects: 70
Study 28150856 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary rehabilitation alone
Number of subjects: 70
Study 26714460 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT) - two gym-based supervised sessions/week and one home-based session/week, consisting of four 4-minute intervals at approximately 90% of maximum heart rate with 3-minute recovery periods.
Number of subjects: 0
Study 26714460 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle physical activity - participants receive a resource pack and pedometer, aiming to increase daily steps to 10,000 steps/day.
Number of subjects: 0
Study 23988418 — intervention group
Group type: EXPERIMENTAL
Intervention: DBGT (double-brewed green tea), 500 mL daily until recurrence or during a follow-up of 18 months
Number of subjects: 16
Study 23988418 — intervention group
Group type: EXPERIMENTAL
Intervention: DBGT adherence
Number of subjects: 16
Study 23988418 — intervention group
Group type: EXPERIMENTAL
Intervention: DBGT intervention
Number of subjects: 16
Study 21996391 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised endurance/resistance training in addition to usual care (ET, n = 44)
Number of subjects: 64
Study 21996391 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone (UC, n = 20)
Number of subjects: 64
Study 18423747 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin
Number of subjects: 76
Study 18423747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 16503680 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training (30 seconds at 28 Hz, 10-mm amplitude, 6 times per training session) combined with contract-release stretching
Number of subjects: 19
Study 16503680 — intervention group
Group type: COMPARATOR
Intervention: Control group (contract-release stretching only)
Number of subjects: 19
Study 12758210 — intervention group
Group type: EXPERIMENTAL
Intervention: NTP regimen
Number of subjects: 360
Study 12758210 — intervention group
Group type: COMPARATOR
Intervention: 4FDC regimen
Number of subjects: 360
Study 11010055 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 187
Study 11010055 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 80 mg
Number of subjects: 187
Study 9059293 — intervention group
Group type: EXPERIMENTAL
Intervention: Power Doppler sonography
Number of subjects: 22
Study 9059293 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy results
Number of subjects: 22
Study 9059293 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical analysis
Number of subjects: 22
Study 8420606 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammographic film classified as P2 or DY
Number of subjects: 0
Study 8420606 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormality reported by radiologist
Number of subjects: 0
Study 8420606 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormality reported by nurse examiner
Number of subjects: 0
Study 3773721 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training program (3 d/wk, 48 min/d, at 65% to 85% of heart rate reserve)
Number of subjects: 34
Study 3773721 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training program
Number of subjects: 34
Study 3773721 — intervention group
Group type: COMPARATOR
Intervention: Control (untrained state)
Number of subjects: 34
Study 31740428 — intervention group
Group type: EXPERIMENTAL
Intervention: GKT137831 400 mg BID for 48 weeks
Number of subjects: 142
Study 31740428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 29329422 — intervention group
Group type: EXPERIMENTAL
Intervention: Proscriptive health message
Number of subjects: 529
Study 29329422 — intervention group
Group type: COMPARATOR
Intervention: Prescriptive health message
Number of subjects: 529
Study 29329422 — intervention group
Group type: EXPERIMENTAL
Intervention: Proscriptive health message (for male participants drinking above recommended limits)
Number of subjects: 529
Study 27298017 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumacaftor (600 mg once daily) plus ivacaftor (250 mg every 12 h)
Number of subjects: 1108
Study 27298017 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumacaftor (400 mg every 12 h) plus ivacaftor (250 mg every 12 h)
Number of subjects: 1108
Study 27298017 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumacaftor (600 mg per day) plus ivacaftor (250 mg every 12 h)
Number of subjects: 1108
Study 27298017 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumacaftor (400 mg/12 h) plus ivacaftor (250 mg every 12 h)
Number of subjects: 1108
Study 27298017 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumacaftor/ivacaftor (both doses)
Number of subjects: 1108
Study 27298017 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumacaftor/ivacaftor
Number of subjects: 1108
Study 27298017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1108
Study 24571855 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile acuity training
Number of subjects: 15
Study 24571855 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham tactile acuity training)
Number of subjects: 15
Study 23765950 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe eosinophilia (≥ 1.0 × 10(9) /L)
Number of subjects: 356196
Study 23765950 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild eosinophilia (≥ 0.5‐1.0 × 10(9) /L)
Number of subjects: 356196
Study 23765950 — intervention group
Group type: EXPERIMENTAL
Intervention: Any eosinophilia
Number of subjects: 356196
Study 20225703 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient mixture (alpha‐tocopherol acetate, ascorbic acid, cholecalcipherol, green tea extract)
Number of subjects: 32
Study 20225703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 20225703 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient mixture
Number of subjects: 32
Study 17959703 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin infusion
Number of subjects: 47
Study 17959703 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside infusion
Number of subjects: 47
Study 16983396 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-tomato lycopene supplementation
Number of subjects: 0
Study 16983396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14733451 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular olanzapine (10.0 mg)
Number of subjects: 311
Study 14733451 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular haloperidol (7.5 mg)
Number of subjects: 311
Study 14733451 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular placebo
Number of subjects: 311